Chula Vista, CANCT07560150Now EnrollingIRB Ready

Pharmacokinetics Clinical Trial in Chula Vista, CA

Access cutting-edge pharmacokinetics treatment through this clinical trial at a research site in Chula Vista. Study-provided care at no cost to qualified participants.

Sponsored by Amphastar Pharmaceuticals, Inc.

Quick Self-Assessment

See if you qualify for this Chula Vista location

Preparing your pre-screening questions…

Expert Care in Chula Vista

Access pharmacokinetics specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related pharmacokinetics treatment provided free

Apply for This Chula Vista Location

Check if you qualify for this pharmacokinetics clinical trial in Chula Vista, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Chula Vista

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Chula Vista site if eligible
  4. 4Begin participation

About This Pharmacokinetics Study in Chula Vista

This study is a randomized, double-blinded, two-treatment, two-period, two-sequence crossover pivotal Biosimilar study. The purpose of this study is to establish pharmacokinetic (PK) and pharmacodynamic (PD) biosimilarity of proposed biosimilar I004 and the US-approved NovoLog.

Sponsor: Amphastar Pharmaceuticals, Inc.

Who Can Participate

Inclusion Criteria

Upon review, agree to participate and sign informed consent.
Healthy male and female subjects ≥ 18 to ≤ 65 years of age.
Body mass index (BMI) ≥ 18.5 to ≤ 29.9 kg/m2
Weight ≥ 50 kg.
Fasting plasma glucose of \< 100 mg/dL (5.5 mmol/L) measured with YSI at site; one repeat test is allowed.
HbA1c \< 5.7%.
Non-smoker for ≥ 3 months prior to Screening.
Female candidates must be \> 1 year post-menopausal, surgically sterile, or practicing a clinically acceptable form of birth control and confirmed by negative serum pregnancy test at Screening.

Exclusion Criteria

History of diabetes mellitus.
Resting blood pressure (BP) \> 140/90 mmHg or \< 90/60 mmHg. Subjects BP may be re-checked.
Participation in an investigational drug/device study within 30 days or 5 half-lives within the last dose of any study drug, whichever is longer.
History of any serious adverse reaction or hypersensitivity to any of the investigational product components.
Have significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders or abnormalities, or other major systemic disease that, according to the investigator, would unduly risk the subject's safety or may impact the conduct of the study.
Subject shows evidence of significant active neuropsychiatric disease, including taking prescription medication for such diseases (including anti-depressant/anti-anxiety medication).
Presence of clinically significant physical, laboratory, or ECG findings at Screening that, in the opinion of the Investigator, may interfere with any aspect of study conduct or interpretation of results, or may present a safety issue to that particular subject (laboratory results may be re-checked once on a separate day per Investigator discretion).
Long QT syndrome or family history of long QT syndrome or corrected QT interval (QTcF) \> 450 ms in men, \> 470 ms in women at Screening.
Liver function test results of AST and/or ALT ≥ 2.5 upper normal limit (ULN)
Subject has a history of syncope.
History of any major surgery within 6 months.
History of any active infection, other than mild viral illness within 30 days prior to dosing.
History of blood clots (e.g., deep vein thrombosis or embolism) or a frequent appearance in 1st degree relatives as judged by the Investigator.
Known history or positive test of hepatitis B surface antigen (HBsAG), hepatitis C antibody (HCV Ab), or human immunodeficiency virus type 1 (HIV-1) or 2 (HIV-2) antibody.
History of systemic glucocorticoid use within 3 months before screening.
History of alcohol abuse as judged by the Investigator within approximately 1 year. Average weekly alcohol intake \> 21 units/week (males) and \> 14 units/week (females) or are unwilling to stop alcohol consumption from 24 hours prior to each dosing until discharged from the clinical research unit (CRU). Positive alcohol test at Screening. (One unit of alcohol equals about 250 mL of beer or lager, one glass of wine, or 20 mL of spirits).
History of illicit drug abuse, including marijuana, within approximately 1 year or evidence of current use as judged by the Investigator. Positive drug test at Screening.
Donation or loss of \> 500 mL of blood within 56 days.
Chronic use of over-the-counter or prescription medication within 7 or 14 days prior to dosing (apart from vitamin/mineral supplements, occasional paracetamol, or birth control methods \[Desogestrel is not allowed\]).
Unable to comply with the safety monitoring requirements of this clinical study or is considered by the investigator to be an unsuitable candidate for the study.
Women who are pregnant of breast-feeding.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Chula Vista?

Yes, this clinical trial (NCT07560150) has an active research site in Chula Vista, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Pharmacokinetics Treatment Options in Chula Vista, CA

If you're searching for pharmacokinetics treatment options in Chula Vista, CA, this clinical trial (NCT07560150) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Chula Vista research site is actively enrolling participants for this clinical trial. You'll receive care from experienced pharmacokinetics specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all pharmacokinetics clinical trials near you to find additional studies recruiting in your area.

More Neuroendocrine Tumors Trials in Chula Vista, CA

See all neuroendocrine tumors clinical trials recruiting in Chula Vista — not just this study.

Browse Neuroendocrine Tumors Trials in Chula Vista →

Browse More Trials by Condition

Neuroendocrine Tumors TrialsEssential Tremor TrialsPulmonary Hypertension TrialsInterstitial Cystitis TrialsAll Conditions →

Ready to Join in Chula Vista?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Chula Vista, CA